Research ArticleOriginal Research

Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal

Quyen Ngo-Metzger, Samuel Zuvekas, Paul Shafer, Howard Tracer, Amanda E. Borsky and Arlene S. Bierman
The Journal of the American Board of Family Medicine November 2019, 32 (6) 807-817; DOI: https://doi.org/10.3122/jabfm.2019.06.180313

References

  1. 1.↵
    1. Benjamin EJ,
    2. Virani SS,
    3. Callaway CW,
    4. et al
    . Heart Disease and Stroke Statistics—2018 Update: a report from the American Heart Association. Circulation 2018;137:e67–e492.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH,
    4. et al
    . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1e–S45.
    OpenUrl
  3. 3.↵
    1. Koskinas KC,
    2. Siontis GCM,
    3. Piccolo R,
    4. et al
    . Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 2018;39:1172–1180.
    OpenUrlPubMed
  4. 4.↵
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Rodriguez F,
    2. Maron DJ,
    3. Knowles JW,
    4. Virani SS,
    5. Lin S,
    6. Heidenreich PA
    . Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2017;2:47–54.
    OpenUrl
  7. 7.↵
    1. Navarese EP,
    2. Robinson JG,
    3. Kowalewski M,
    4. et al
    . Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018;319:1566–1579.
    OpenUrl
  8. 8.↵
    1. Booth JN 3rd.,
    2. Colantonio LD,
    3. Rosenson RS,
    4. et al
    . Healthcare utilization and statin re-initiation among medicare beneficiaries with a history of myocardial infarction. J Am Heart Assoc 2018;7(10).
  9. 9.↵
    1. Johansen ME,
    2. Green LA,
    3. Sen A,
    4. Kircher S,
    5. Richardson CR
    . Cardiovascular risk and statin use in the United States. Ann Fam Med 2014;12:215–223.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Peters SAE,
    2. Colantonio LD,
    3. Zhao H,
    4. et al
    . Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol 2018;71:1729–1737.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Rosenson RS,
    2. Farkouh ME,
    3. Mefford M,
    4. et al
    . Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014. J Am Coll Cardiol 2017;69:2696–2706.
    OpenUrlFREE Full Text
  12. 12.↵
    1. Salami JA,
    2. Warraich H,
    3. Valero-Elizondo J,
    4. et al
    . National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey. JAMA Cardiol 2017;2:56–65.
    OpenUrlCrossRef
  13. 13.↵
    1. Olufade T,
    2. Zhou S,
    3. Anzalone D,
    4. et al
    . Initiation patterns of statins in the 2 years after release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a large US health plan. J Am Heart Assoc 2017;6(5).
  14. 14.↵
    1. Okerson T,
    2. Patel J,
    3. DiMario S,
    4. Burton T,
    5. Seare J,
    6. Harrison DJ
    . Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on statin treatment patterns and low-density lipoprotein cholesterol in atherosclerotic cardiovascular disease patients. J Am Heart Assoc 2017;6(3).
  15. 15.↵
    1. Pool LR,
    2. Ning H,
    3. Lloyd-Jones DM,
    4. Allen NB
    . Trends in racial/ethnic disparities in cardiovascular health among US adults from 1999–2012. J Am Heart Assoc 2017;6(9).
  16. 16.↵
    1. Lu Y,
    2. Ezzati M,
    3. Rimm EB,
    4. Hajifathalian K,
    5. Ueda P,
    6. Danaei G
    . Sick Populations and sick subpopulations: reducing disparities in cardiovascular disease between Blacks and whites in the United States. Circulation 2016;134:472–485.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Kuzawa CW,
    2. Sweet E
    . Epigenetics and the embodiment of race: developmental origins of US racial disparities in cardiovascular health. Am J Hum Biol 2009;21:2–15.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Lewey J,
    2. Shrank WH,
    3. Bowry AD,
    4. Kilabuk E,
    5. Brennan TA,
    6. Choudhry NK
    . Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 2013;165:665–678, 678.e661.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Agency for Healthcare Research and Quality. Survey background. 2009. Available from: https://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp. Accessed June 7, 2018.
  20. 20.↵
    1. Hill SC,
    2. Zuvekas SH,
    3. Zodet MW
    . Implications of the accuracy of MEPS prescription drug data for health services research. Inquiry 2011;48:242–259.
    OpenUrlPubMed
  21. 21.↵
    1. Machlin S,
    2. Cohen J,
    3. Elixhauser A,
    4. Beauregard K,
    5. Steiner C
    . Sensitivity of household reported medical conditions in the medical expenditure panel survey. Med Care 2009;47:618–825.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Stata Statistical Software: Release 14 [Computer Program]. College Station, TX. StataCorp LP; 2015.
  23. 23.↵
    1. Ngo-Metzger Q,
    2. Zuvekas SH,
    3. Bierman AS
    . Estimated impact of US Preventive Services Task Force recommendations on use and cost of statins for cardiovascular disease prevention. J Gen Intern Med 2018;33:1317–1323.
    OpenUrl
  24. 24.↵
    1. Borsky A,
    2. Zhan C,
    3. Miller T,
    4. Ngo-Metzger Q,
    5. Bierman AS,
    6. Meyers D
    . Few Americans receive all high-priority, appropriate clinical preventive services. Health Aff (Millwood) 2018;37:925–928.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. McGlynn EA,
    2. Asch SM,
    3. Adams J,
    4. et al
    . The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635–2645.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Fang J,
    2. Ayala C,
    3. Luncheon C,
    4. Ritchey M,
    5. Loustalot F
    . Use of outpatient cardiac rehabilitation among heart attack survivors—20 states and the District of Columbia, 2013 and four states, 2015. MMWR Morb Mortal Wkly Rep 2017;66:869–873.
    OpenUrl
  27. 27.↵
    1. Thomas RJ,
    2. Balady G,
    3. Banka G,
    4. et al
    . 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 2018;71:1814–1837.
    OpenUrlFREE Full Text
  28. 28.↵
    1. Mosca L,
    2. Linfante AH,
    3. Benjamin EJ,
    4. et al
    . National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499–510.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Keyhani S,
    2. Scobie JV,
    3. Hebert PL,
    4. McLaughlin MA
    . Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension 2008;51:1149–1155.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Mosca L,
    2. Barrett-Connor E,
    3. Wenger NK
    . Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011;124:2145–2154.
    OpenUrlFREE Full Text
  31. 31.↵
    1. Baigent C,
    2. Keech A,
    3. Kearney PM,
    4. et al
    . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Enriquez JR,
    2. Pratap P,
    3. Zbilut JP,
    4. Calvin JE,
    5. Volgman AS
    . Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gender Med 2008;5:53–61.
    OpenUrl
  33. 33.↵
    1. Gu A,
    2. Kamat S,
    3. Argulian E
    . Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999–2014. Diabetes Res Clin Pract 2018;139:1–10.
    OpenUrl
  34. 34.↵
    1. Gamboa CM,
    2. Colantonio LD,
    3. Brown TM,
    4. Carson AP,
    5. Safford MM
    . Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017;6(5).
  35. 35.↵
    1. Adedinsewo D,
    2. Taka N,
    3. Agasthi P,
    4. Sachdeva R,
    5. Rust G,
    6. Onwuanyi A
    . Prevalence and factors associated with statin use among a nationally representative sample of US adults: National Health and Nutrition Examination Survey, 2011–2012. Clin Cardiol 2016;39:491–496.
    OpenUrl
  36. 36.↵
    1. Qureshi WT,
    2. Kaplan RC,
    3. Swett K,
    4. et al
    . American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk: implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc 2017;6(5).
  37. 37.↵
    1. Kripalani S,
    2. Goggins K,
    3. Nwosu S,
    4. et al
    . Medication nonadherence before hospitalization for acute cardiac events. J Health Commun 2015;20(Suppl 2):34–42.
    OpenUrl
  38. 38.↵
    1. Havranek EP,
    2. Mujahid MS,
    3. Barr DA,
    4. et al
    . Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2015;132:873–898.
    OpenUrlFREE Full Text
  39. 39.↵
    1. Ndumele CD,
    2. Baer HJ,
    3. Shaykevich S,
    4. Lipsitz SR,
    5. Hicks LS
    . Cardiovascular disease and risk in primary care settings in the United States. Am J Cardiol 2012;109:521–526.
    OpenUrlPubMed
  40. 40.↵
    1. Spatz ES,
    2. Sheth SD,
    3. Gosch KL,
    4. et al
    . Usual source of care and outcomes following acute myocardial infarction. J Gen Intern Med 2014;29:862–869.
    OpenUrl
  41. 41.↵
    The Patient Protection and Affordable Care Act. In. Vol 42 U.S.C. § 180012010.
  42. 42.↵
    U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services, The Center for Consumer Information & Insurance Oversight,. Affordable Care Act Implementation FAQs—Set 18. n.d. Available from: https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs18.html.
  43. 43.↵
    1. Watanabe JH,
    2. Kazerooni R,
    3. Bounthavong M
    . Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm 2014;20:43–50.
    OpenUrlPubMed
  44. 44.↵
    1. Choudhry NK,
    2. Avorn J,
    3. Glynn RJ,
    4. et al
    . Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088–2097.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Bibbins-Domingo K,
    2. Grossman DC,
    3. Curry SJ,
    4. et al
    . Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016;316:1997–2007.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Brandeis University. Zero copayment for certain statin prescriptions. n.d. Available from: https://www.brandeis.edu/humanresources/benefits/pdfs/2018/OptumRx_Statin_Prescriptions.pdf. Accessed August 6, 2018.
  47. 47.↵
    1. Karaca-Mandic P,
    2. Swenson T,
    3. Abraham JM,
    4. Kane RL
    . Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res 2013;48:1311–1333.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Tanner RM,
    2. Safford MM,
    3. Monda KL,
    4. et al
    . Primary care physician perspectives on barriers to statin treatment. Cardiovasc Drugs Ther 2017;31:303–309.
    OpenUrl
  49. 49.↵
    1. Ju A,
    2. Hanson CS,
    3. Banks E,
    4. et al
    . Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract 2018;68:e408–e419.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Booth JN 3rd.,
    2. Colantonio LD,
    3. Chen L,
    4. et al
    . Statin discontinuation, reinitiation, and persistence patterns among medicare beneficiaries after myocardial infarction: a cohort study. Circ Cardiovasc Qual Outcomes 2017;10(10).
  51. 51.↵
    1. Izuka NJ,
    2. Alexander MAW,
    3. Balasooriya-Smeekens C,
    4. Mant J,
    5. De Simoni A
    . How do stroke survivors and their carers use practitioners' advice on secondary prevention medications? Qualitative study of an online forum. Fam Pract 2017;34:612–620.
    OpenUrl
  52. 52.↵
    1. Ofori-Asenso R,
    2. Jakhu A,
    3. Zomer E,
    4. et al
    . Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 2018;73:813–819.
    OpenUrl
  53. 53.↵
    1. Inselman J,
    2. Branda M,
    3. Castaneda-Guarderas A,
    4. et al
    . Uptake and documentation of the use of an encounter decision aid in usual practice: a retrospective analysis of the use of the statin/aspirin choice decision aid. Med Decis Making 2016;36:557–561.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Zuvekas SH,
    2. Olin GL
    . Validating household reports of health care use in the medical expenditure panel survey. Health Serv Res 2009;44(5 Pt 1):1679–1700.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Cheak-Zamora NC,
    2. Wyrwich KW,
    3. McBride TD
    . Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Qual Life Res 2009;18:727–735.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Mercado C,
    2. DeSimone AK,
    3. Odom E,
    4. Gillespie C,
    5. Ayala C,
    6. Loustalot F
    . Prevalence of cholesterol treatment eligibility and medication use among adults–United States, 2005–2012. MMWR Morb Mortal Wkly Rep 2015;64:1305–1311.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Johansen ME,
    2. Hefner JL,
    3. Foraker RE
    . Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol 2015;115:1507–1512.
    OpenUrl
  58. 58.↵
    1. Sarpong EM,
    2. Zuvekas SH
    . Trends in statin therapy among adults (age ≥ 18), United States, 2000 to 2011. In: Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville, MD: Agency for Healthcare Research and Quality (US); 2001.
  59. 59.↵
    1. Sarpong EM,
    2. Zuvekas SH
    . Changes in statin therapy among adults (age ≥ 18) by selected characteristics, United States, 2000–2001 to 2010–2011. In: Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville, MD: Agency for Healthcare Research and Quality (US); 2001.
  60. 60.↵
    IMS Institute for Health Informatics. Medicines Use and Spending in the U.S., A Review of 2015 and Outlook to 2020. 2016. Available from: https://morningconsult.com/wp-content/uploads/2016/04/IMS-Institute-US-Drug-Spending-2015.pdf.
  61. 61.↵
    1. Toth PP,
    2. Patti AM,
    3. Giglio RV,
    4. et al
    . Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs 2018;18:157–173.
    OpenUrl
  62. 62.↵
    1. Grundy SM,
    2. Stone NJ,
    3. Bailey AL,
    4. et al
    . AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol 2018;2018:25709.
    OpenUrl
  63. 63.↵
    1. Hirsch AT,
    2. Criqui MH,
    3. Treat-Jacobson D,
    4. et al
    . Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–1324.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Cohen JD,
    2. Aspry KE,
    3. Brown AS,
    4. et al
    . Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. J Clin Lipidol 2013;7:573–609.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords